Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Invested Capital (2021 - 2026)

Indivior Pharmaceuticals has reported Invested Capital over the past 6 years, most recently at -$144.0 million for Q1 2026.

  • For Q1 2026, Invested Capital rose 46.07% year-over-year to -$144.0 million; the TTM value through Mar 2026 reached -$144.0 million, up 46.07%, while the annual FY2025 figure was -$69.0 million, 1625.0% down from the prior year.
  • Invested Capital for Q1 2026 was -$144.0 million at Indivior Pharmaceuticals, down from -$69.0 million in the prior quarter.
  • Over five years, Invested Capital peaked at $309.0 million in Q4 2022 and troughed at -$310.0 million in Q3 2024.
  • A 5-year average of -$118.1 million and a median of -$161.0 million in 2024 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: tumbled 1625.0% in 2025 and later soared 46.07% in 2026.
  • Year by year, Invested Capital stood at $309.0 million in 2022, then tumbled by 81.88% to $56.0 million in 2023, then crashed by 107.14% to -$4.0 million in 2024, then tumbled by 1625.0% to -$69.0 million in 2025, then tumbled by 108.7% to -$144.0 million in 2026.
  • Business Quant data shows Invested Capital for INDV at -$144.0 million in Q1 2026, -$69.0 million in Q4 2025, and -$189.0 million in Q3 2025.